THE ARISING · Longevity & Healthspan
FDA Agrees Phase 3 Design for Zervimesine in Lewy Body Dementia
Families living with dementia with Lewy bodies have no approved drug that slows the disease. According to Longevity.Technology's report, a company now has a plan for a pivotal trial, with key design elements agreed with the regulator, that could test one.
Longevity.Technology reports that Cognition Therapeutics has reached alignment with the U.S. Food and Drug Administration on key elements of a planned pivotal Phase 3 study of zervimesine, also known as CT1812, in dementia with Lewy bodies. This article is based on that report. The company announcement and the underlying trial data were not reviewed.
Dementia with Lewy bodies, or DLB, is a brain disease that affects thinking, movement and behavior. According to the report, the company's release says no approved drugs slow its progression. It cites an estimated 1.4 million Americans living with the disease.
Here is what the planned trial looks like, according to the report. It would enroll people with mild-to-moderate DLB. Participants would be randomly assigned to take either 100 mg of zervimesine as a pill once a day, or a placebo, for nine months.
The main measure of success would be the neuropsychiatric inventory score for hallucinations and delusions, known as NPI-2. A key secondary measure would be the Alzheimer's Disease Cooperative Study Activities of Daily Living scale. It assesses daily function, such as how well a person manages everyday tasks.
The report says the company claims earlier Phase 2 studies showed slowing of DLB progression across neuropsychiatric, cognitive, motor and functional measures. It also says the company describes the drug as generally well tolerated. These are the company's claims as relayed by the report. They have not been checked here, and Phase 2 studies are typically smaller and less conclusive than Phase 3 trials.
What this means for families is limited for now. Agreement on trial design is a step toward a trial. It is not evidence that the drug works, and it is not an approval. The report does not give an enrollment size or a start date, so it is not yet clear who could take part or when.
Still, the choice of endpoints is worth noting. Hallucinations, delusions and daily function are things families may see and live with. A result on those measures could be easy to understand in everyday terms. Whether zervimesine can deliver one is the open question the Phase 3 study would address.
What to watch next
The announcement of enrollment size, trial sites and a start date, and then the Phase 3 results themselves.